Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients

American Journal of Health-System Pharmacy

Volumn 61, Issue 18, 2004, Pages 1917-1921

  Sweet, Burgunda V ^a,b   Townsend, Kevin A ^c,d   Tsai, Christine Y ^b,e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c PFIZER INC   (United States)

^d Department of Pharmacy Practice   (United States)

^e SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Ambulatory care; Antiinflammatory agents; Celecoxib; Gastrointestinal diseases; Ibuprofen; Managed care systems; Naproxen; Rofecoxib; Toxicity

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM;

EID: 8344252658     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.18.1917     Document Type: Article

References (13)

1. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998; 105(1B):31S-8S.
2. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications. J Rheumatol. 1999; 26(suppl):18-24.
3. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rhuematoid arthritis. The CLASS Study: a randomized controlled trial. JAMA. 2000; 284:1247-55.
4. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343:1520-8.
5. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002; 325:619-26.
6. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl. 1991; 28:6-10.
7. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med. 1995; 123:241-9.
8. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115:787-96.
9. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996; 156:1530-6.
10. Cox ER, Motheral B, Frisse M et al. Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy. Am J Manag Care. 2003; 9:735-42.
11. Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care. 2003; 9:785-94.
12. El-Serag HB, Graham DY, Richardson P et al. Prevention of complicated ulcer disease among chronic users of nonsteroidal and-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002; 162:2105-10.
13. Spiegel BM, Targownik L, Dulai GS et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 2003; 138:795-806.